cenobamate Xcopri
Selected indexed studies
- Cenobamate (Xcopri) for focal seizures. (Med Lett Drugs Ther, 2020) [PMID:32970044]
- ** (, 2023) [PMID:38320077]
- Cenobamate (XCOPRI): Can preclinical and clinical evidence provide insight into its mechanism of action? (Epilepsia, 2020) [PMID:33063849]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. (2020) pubmed
- Cenobamate. (2012) pubmed
- Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug-Drug Interactions and Tolerability. (2021) pubmed
- Cenobamate: First Approval. (2020) pubmed
- The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. (2021) pubmed
- Cenobamate (Xcopri) for focal seizures. (2020) pubmed
- PMID:38320077 (2023) pubmed
- Cenobamate (XCOPRI): Can preclinical and clinical evidence provide insight into its mechanism of action? (2020) pubmed
- PMID:38295220 (2023) pubmed
- Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. (2020) pubmed